Gavriel Rosenfeld talks to Dr Ronni Cohn about living with Duchenne

Gavriel Rosenfeld talks to Dr Ronni Cohn about living with Duchenne

On Wednesday 17th March the Duchenne Research Fund hosted a virtual evening to share updates with supporters about research funded by the charity. Our co-founders Kerry & Doron Rosenfeld welcomed more than 200 viewers from across five continents who came together...

Solid announces collaboration with Ultragenyx

Ultragenyx Pharmaceutical and Solid Biosciences have announced a strategic collaboration and license agreement to focus on the development and commercialisation of new gene therapies for Duchenne. The collaboration brings together Solid’s expertise in muscle biology...

Update on Ignite DMD from Solid Biosciences

Solid Biosciences has issued an update on IGNITE DMD, the Phase I/II clinical study with its microdystrophin gene therapy, SGT-001. The most recent child dosed in the study has experienced a serious adverse event (SAE), and thankfully, he is now improving. He is being...

Gene therapy for Duchenne: latest news

Five years ago we identified gene therapy as a viable treatment for Duchenne. Today we are reflecting on the exciting and inspiring events of the past week in the gene therapy arena which are now bringing hope and cautious optimism to the Duchenne community. We have...

Solid Biosciences clear to resume IGNITE DMD

Message from Solid Biosciences: “We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD, our clinical trial investigating SGT-001 as a potential treatment for Duchenne muscular dystrophy (DMD). SGT-001 is a microdystrophin gene...
DRF raises £1.2 million to help beat Duchenne

DRF raises £1.2 million to help beat Duchenne

The Duchenne Research Fund raised £1.2 million at its ‘The Time Is Now’ Gala Dinner on 5 May at the Lancaster London Hotel to help find a cure for Duchenne muscular dystrophy – the biggest genetic killer of children worldwide. The funds raised will enable the DRF to...
DRF’s funding of Solid GT leads to $42.5 million investment

DRF’s funding of Solid GT leads to $42.5 million investment

We are thrilled that the money raised through the Duchenne Research Fund’s 2013 dinner and donations since then have enabled us to seed fund the incredible Solid GT project, which has today received industry investment (read the press release below). While gene...
Albourne raises £155,000 for DRF

Albourne raises £155,000 for DRF

We are immensely grateful to Albourne Partners and their supporters for raising more than £155,000 for our projects at their incredible performance of ‘The Importance of Being Lewis’ on 7 October. The event was held to honour the memory of Jacques Joubert...

Gene therapy breakthrough in muscular dystrophy dogs

The Duchenne Research Fund is incredibly proud of Dr Dongsheng Duan – an important Scientific Advisory Board member of Solid GT, a gene therapy programme pioneered by Solid Biosciences and that we helped to fund. Dr Duan’s latest gene therapy work on...